Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Newsletter Article
|
Achieve Life Sciences (ACHV: $5.03) accelerates rise, up 9.1% in 2 days; +42c [9.1%] Vol Index 1.8 [1 is avg]News Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd May 15, 2024Digital Resources/Online E-Resources |
|
2 |
Material Type: Newsletter Article
|
European Society of Cardiology: Weight Loss Drug Linked With Reduced Need for Diuretics in Heart Failure PatientsTargeted News Service, 2024Targeted News ServiceDigital Resources/Online E-Resources |
|
3 |
Material Type: Newsletter Article
|
Achieve Life Sciences (ACHV: $4.81) up 6.2% in 2 days, hits 101-day high; +28c [6.2%] Vol Index 1.6 [1 is avg]News Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd May 14, 2024Digital Resources/Online E-Resources |
|
4 |
Material Type: Newsletter Article
|
Achieve Life Sciences (ACHV: $4.61) lifts 1.8% on rising relative strength; reports Loss of $6.5m; +8c [1.8%] Vol Index 1.5 [1 is avg]News Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd May 11, 2024Digital Resources/Online E-Resources |
|
5 |
Material Type: Newsletter Article
|
New Pulmonary Syndrome Linked to Covid-19 DiscoveredCE Noticias Financieras, 2024CE Noticias Financieras English, Latin America - Distributed by ContentEngine LLCDigital Resources/Online E-Resources |
|
6 |
Material Type: Newsletter Article
|
Achieve Life Sciences (ACHV: $4.53) down 4.2% in 2 days; -20c [4.2%]News Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd May 10, 2024Digital Resources/Online E-Resources |
|
7 |
Material Type: Newsletter Article
|
Achieve Life Sciences (ACHV: $4.70) decreases; -3c [0.6%]News Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd May 9, 2024Digital Resources/Online E-Resources |
|
8 |
Material Type: Newsletter Article
|
Achieve Life Sciences (ACHV: $4.73) continues significant uptrend, gains 3.5%; +16c [3.5%]News Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd May 8, 2024Digital Resources/Online E-Resources |
|
9 |
Material Type: Newsletter Article
|
National Yang Ming Chiao Tung Univ Seeks Patent for Neurovascular Age Prediction System Based on White Matter and Method ThereofGlobal IP News. Medical Patent News, 2024Copyright© 2024, Globalipnews.comDigital Resources/Online E-Resources |
|
10 |
Material Type: Newsletter Article
|
Achieve Life Sciences Announces Publication Of Cytisinicline Vaping Cessation Trial Results In JAMA Internal Medicine; Phase 2 ORCA-V1 Trial Showed Treatment With Cytisinicline More Than Doubled Odds Of Quitting E-Cigarettes Compared With PlaceboBenzinga Newswires, 20242020 Benzinga.com - Benzinga does not provide investment advice. All rights reserved.Digital Resources/Online E-Resources |
|
11 |
Material Type: Newsletter Article
|
Press Release: Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal MedicineDow Jones Institutional News, 2024Copyright Dow Jones & Company Inc. May 6, 2024Digital Resources/Online E-Resources |
|
12 |
Material Type: Newsletter Article
|
Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal MedicineNASDAQ OMX's News Release Distribution Channel, 2024GlobeNewswire, Inc.Digital Resources/Online E-Resources |
|
13 |
Material Type: Newsletter Article
|
Society for Cardiovascular Angiography Interventions: TAVR Is Associated With Lower In-Hospital Complications in Patients With Aortic Stenosis and Cardiogenic Shock Compared to SAVRTargeted News Service, 2024Targeted News ServiceDigital Resources/Online E-Resources |
|
14 |
Material Type: Newsletter Article
|
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business UpdateNASDAQ OMX's News Release Distribution Channel, 2024GlobeNewswire, Inc.Digital Resources/Online E-Resources |
|
15 |
Material Type: Newsletter Article
|
Kyowa Kirin to Present a Safety Meta-Analysis of NOURIANZ® (istradefylline) and Other Parkinson's Disease Add-On TherapiesPR Newswire, 2024Copyright PR Newswire Association LLC Apr 12, 2024Digital Resources/Online E-Resources |
|
16 |
Material Type: Newsletter Article
|
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical StudyNASDAQ OMX's News Release Distribution Channel, 2024GlobeNewswire, Inc.Digital Resources/Online E-Resources |
|
17 |
Material Type: Newsletter Article
|
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled HypertensionBusiness Wire, 2024Copyright Business Wire 2024Digital Resources/Online E-Resources |
|
18 |
Material Type: Newsletter Article
|
Eight-bagger Applied Therapeutics (APLT: $6.38) increases; +5c [0.8%]News Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd Apr 3, 2024Digital Resources/Online E-Resources |
|
19 |
Material Type: Newsletter Article
|
American Academy of Sleep Medicine: Health Care Utilization is Increased in High-Risk Children Who Have a Sleep DisorderTargeted News Service, 2024Targeted News ServiceDigital Resources/Online E-Resources |
|
20 |
Material Type: Newsletter Article
|
Applied Therapeutics (APLT: $6.30) plunges 7.4% on slipping relative strength; -50c [7.4%] Vol Index 1.2 [1 is avg]News Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd Apr 2, 2024Digital Resources/Online E-Resources |